Jubilant Pharma arm to raise Rs 3,186 crore loan from Standard Chartered Bank to repay debt
New Delhi: Jubilant Pharma Holdings on Wednesday said it has signed an agreement with Standard Chartered Bank for a five-year loan of USD 400 million, about Rs 3,186 crore. Majority of the amount will be used for repayment of existing term loan and debt bonds, the company said in a regulatory filing.
While the term loan and bonds aggregate to USD 350 million, about Rs 2,787 crore, the company is raising another tranche of USD 50 million (about Rs 400 crore) for capital expenditure.
"Jubilant Pharmova Limited's wholly-owned subsidiary Jubilant Pharma Limited today announced that its subsidiary Jubilant Pharma Holdings Inc (JPHI) has entered in an agreement with Standard Chartered Bank for a five-year loan facility for repayment of existing term loan and bonds aggregating USD 350 million and additional tranche of USD 50 million for future growth capex," the company said.
Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies.
Next Story
